I6658
Isradipine
≥98% (HPLC), calcium channel blocker, solid
别名:
4-(4-Benzofurazanyl)-1,-4-dihydro-2,6-dimethyl-3,5-pyridinedicarboxylic acid methyl 1-methylethyl ester
登录查看公司和协议定价
选择尺寸
关于此项目
经验公式（希尔记法）:
C19H21N3O5
化学文摘社编号:
分子量:
371.39
MDL编号:
UNSPSC代码:
12352200
PubChem化学物质编号:
NACRES:
NA.77
产品名称
Isradipine, ≥98% (HPLC), solid
描述
Store under nitrogen
质量水平
方案
≥98% (HPLC)
表单
solid
颜色
yellow
溶解性
DMSO: >10 mg/mL
创始人
Novartis
储存温度
2-8°C
SMILES字符串
COC(=O)C1=C(C)NC(C)=C(C1c2cccc3nonc23)C(=O)OC(C)C
InChI
1S/C19H21N3O5/c1-9(2)26-19(24)15-11(4)20-10(3)14(18(23)25-5)16(15)12-7-6-8-13-17(12)22-27-21-13/h6-9,16,20H,1-5H3
InChI key
HMJIYCCIJYRONP-UHFFFAOYSA-N
基因信息
human ... CACNA1C(775), CACNA1D(776), CACNA1F(778), CACNA1S(779), CACNA2D1(781)
正在寻找类似产品? 访问 产品对比指南
应用
Isradipine has been used to explore neuroprotective activity.
生化/生理作用
Isradipine is considered as an active calcium channel blocker, used to treat hypertension.
L-type calcium channel blocker (also referred to as dihydropyridine-type calcium channel blocker); antihypertensive.
L-type calcium channel blocker; antihypertensive.
特点和优势
This compound was developed by Novartis. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.
储存分类代码
11 - Combustible Solids
WGK
WGK 3
闪点(°F)
Not applicable
闪点(°C)
Not applicable
个人防护装备
Eyeshields, Gloves, type N95 (US)
历史批次信息供参考:
分析证书(COA)
Lot/Batch Number
C Savio Chan et al.
Movement disorders : official journal of the Movement Disorder Society, 25 Suppl 1, S63-S70 (2010-02-27)
Parkinson's disease (PD) is a common neurodegenerative disorder of unknown etiology. There is no cure or proven strategy for slowing the progression of the disease. Although there are signs of pathology in many brain regions, the core symptoms of PD
Philip F Copenhaver et al.
Disease models & mechanisms, 4(5), 634-648 (2011-05-21)
A growing body of evidence supports the 'calcium hypothesis' of Alzheimer's disease (AD), which postulates that a variety of insults might disrupt the homeostatic regulation of neuronal calcium (Ca(2+)) in the brain, resulting in the progressive symptoms that typify the
Vincent Malaterre et al.
Drug development and industrial pharmacy, 35(4), 433-439 (2008-11-08)
Push-pull osmotic systems have been developed to deliver poorly soluble drugs in a modified-release fashion. The aim of this study was to investigate the influence of the tablet core factors on the drug release kinetics and loadability. The release kinetics
Dalton James Surmeier et al.
Antioxidants & redox signaling, 14(7), 1289-1301 (2010-08-18)
Parkinson's disease (PD) is a major world-wide health problem afflicting millions of the aged population. Factors that act on most or all cell types (pan-cellular factors), particularly genetic mutations and environmental toxins, have dominated public discussions of disease etiology. Although
Vincent Malaterre et al.
International journal of pharmaceutics, 376(1-2), 56-62 (2009-04-23)
Despite more than 30 years of clinical use, only few studies have been published reporting on the release mechanism underlying the drug delivery from push-pull osmotic pumps (PPOP). The aim of this study is to understand which factors have an
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持